Starting treatment at day 14 post-infection, Martin et al. found, as in [22], that in the case of breast cancer ([23] Fig 4B, 4C) and bladder cancer ([23] Fig 4G, 4H), with anti-PD-1 alone there was hardly any reduction in the tumor volume, but in combination with anti-TGF-β, anti-PD-1 reduced tumor volume significantly; Fig 2C and 2D are in agreement with these results. This evidence concerns the gene TGFB1 and urinary bladder cancer.